Activity of phagocytic granulocytes in patients with prostatic cancer.
Chemilumenescence (CL) occurs due to the phagocytosis of bacteria and of tumor cells by polymorphonuclear neutrophils (PMN). Levels of CL were measured in patients with prostatic cancer and from normal subjects. Patients with advanced disease (stage C, D) showed no elevated CL levels as compared to healthy individuals or patients with minimal disease (stage A, B). Following external radiation therapy in patients with stage A-C prostatic carcinoma high levels of CL were recorded. Estrogen medication also resulted in increased CL levels, while estramustine did not affect phagocytic activity. Intradermal BCG vaccination caused increased PMN activity. Progressive prostatic cancer in hormone treated patients was associated with increased CL as compared to patients with stable or regressive disease.
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001500:BCG Vaccine / Q000627:therapeutic use; D004054:Diethylstilbestrol / Q000031:analogs & derivatives / Q000627:therapeutic use; D004961:Estramustine / Q000627:therapeutic use; D006098:Granulocytes / Q000276:immunology*; D006801:Humans; D008163:Luminescent Measurements; D008297:Male; D010587:Phagocytosis; D011471:Prostatic Neoplasms / Q000276:immunology* / Q000532:radiotherapy / Q000628:therapy
D000970:Antineoplastic Agents; D001500:BCG Vaccine; D004961:Estramustine; D004054:Diethylstilbestrol; C004955:fosfestrol